Other News To Note

• Elusys Therapeutics Inc., of Pine Brook, N.J., said it was awarded additional funding from the U.S. government, valued at $14.5 million, to support expanded human safety studies of ETI-204 (Anthim), an investigational agent for the treatment of anthrax infection following a biowarfare attack.